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Abstract
Background: Gene expression signatures developed to measure the activity of oncogenic signaling pathways have
been used to dissect the heterogeneity of tumor samples and to predict sensitivity to various cancer drugs that
target components of the relevant pathways, thus potentially identifying therapeutic options for subgroups of
patients. To facilitate broad use, including in a clinical setting, the ability to generate data from formalin-fixed,
paraffin-embedded (FFPE) tissues is essential.
Methods: Patterns of pathway activity in matched fresh-frozen and FFPE xenograft tumor samples were generated
using the MessageAmp Premier methodology in combination with assays using Affymetrix arrays. Results
generated were compared with those obtained from fresh-frozen samples using a standard Affymetrix assay. In
addition, gene expression data from patient matched fresh-frozen and FFPE melanomas were also utilized to
evaluate the consistency of predictions of oncogenic signaling pathway status.
Results: Significant correlation was observed between pathway activity predictions from paired fresh-frozen and
FFPE xenograft tumor samples. In addition, significant concordance of pathway activity predictions was also
observed between patient matched fresh-frozen and FFPE melanomas.
Conclusions: Reliable and consistent predictions of oncogenic pathway activities can be obtained from FFPE
tumor tissue samples. The ability to reliably utilize FFPE patient tumor tissue samples for genomic analyses will lead
to a better understanding of the biology of disease progression and, in the clinical setting, will provide tools to
guide the choice of therapeutics to those most likely to be effective in treating a patient’s disease.
Background
Gene expression profiling continues to contribute to
advances in clinical oncology, providing a basis for
understanding the complex biology of tumors, improv-
ing the accuracy of disease diagnosis as well as disease
prognosis, and providing tools to determine which tar-
geted therapeutic agents are likely to be effective in the
treatment of particular tumors. While the majority of
studies have made use of fresh tissue samples so as to
optimize the measurement of gene expression, an ability
to generate reliable and consistent data from formalin-
fixed, paraffin-embedded (FFPE) tissue samples has sev-
eral advantages. First, FFPE tissue samples are readily
available in large numbers across multiple stages of
disease and thus the capability to utilize FFPE tissue
samples broadens the scope of potential studies. Second,
utilization of FFPE tissue samples allows profiling of
archived samples for which patient outcomes are already
known. Third, utilization of FFPE tissue samples allows
profiling of samples from cancers for which all tissue
samples are FFPE after examination of clinicopathologic
characteristics, such as melanoma samples undergoing
an assessment of the prognostic factor of Breslow tumor
thickness, which is most accurately measured using the
entire tumor obtained from an excisional biopsy.
Several studies have investigated methods to facilitate
gene expression profiling from FFPE tissues (for review
see [1]). Good correlations have been observed in gene
expression profiles from fresh-frozen and FFPE lipopo-
lysaccharide-stimulated human bone marrow stromal
cells [2]. With respect to human tumors, concordance
has been found between gene expression profiles from
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by laser capture microdissection [3]. In addition, stu-
dies have shown significant overlap between differen-
tially expressed genes in normal versus cancerous
colon and breast fresh-frozen and FFPE tissues, in
fresh-frozen and FFPE lymphoma and carcinoma, and
in FFPE BRCA1 mutant versus sporadic breast cancers
[4-6]. Furthermore, studies have generated predictive
models from FFPE tissues, including a genomic profile
of nontumoral liver tissue surrounding hepatocellular
carcinoma that correlates with survival and of primary
extremity soft tissue sarcoma that correlates with
metastatic recurrence [7,8]. Finally, concordance has
been observed between unsupervised hierarchical clus-
ters of gene expression data and tumor type of FFPE
carcinomas and the tissue of origin of 3 unknown car-
cinomas has been elucidated [9].
We have previously described methods to generate
gene expression signatures reflecting the activity of a
number of oncogenic signaling pathways [10,11]. These
pathway gene expression signatures have been used to
predict the status of the respective pathways in mouse
as well as human tumors. The opportunity to use these
signatures to dissect the complexity of tumors, rather
than simply using global expression data across >30 k
genes, provides not only a more in-depth understanding
of tumor subtypes, but also reveals opportunities for
novel therapeutic strategies in subgroups of patients, as
this approach has been shown to predict sensitivity to
various cancer drugs that target components of the rele-
vant pathway [10,12]. Given the need to develop tools
that can be applied in a clinical setting, we have focused
on developing the capability to apply these same path-
way analyses to more readily available FFPE tissue
samples.
Methods
Generation of paired fresh-frozen and FFPE xenografts
Six week old female nude mice were injected subcuta-
neously into the lower right abdominal regions near the
hind limb with 4 to 7 million human-derived metastatic
melanoma cell lines suspended in a 2:1 mix of phos-
phate buffered saline (PBS) and Matrigel basement
membrane. All animal protocols were approved by the
Duke University Medical Center Institutional Animal
Care and Use Committee. The melanoma cell lines used
(DM443, DM440, DM366, DM738 and DM6) were
kindly provided by Dr. Hilliard Seigler (Duke University
Medical Center) and were confirmed mycoplasma and
pathogen-free prior to animal studies. Each cell line was
injected into five mice generating a total of 25 xeno-
grafts. Tumors were allowed to grow until approxi-
mately 1000 mm
3 (10 to 15 mm in diameter; two to
four weeks) at which time they were harvested, cleaned
of surrounding connective tissue and skin, divided into
2 pieces and immediately snap frozen or placed in paraf-
ormaldehyde (4% solution in PBS; USB 19943) and fixed
overnight at 4°C.
Human melanoma samples
Eight-10 μm sections were obtained from each patient’s
FFPE block banked at the Department of Pathology at
Duke University Medical Center. All patients were
enrolled after obtaining written informed consent and
tissue samples were collected according to a protocol
approved by the Duke University Medical Center Insti-
tutional Review Board.
RNA preparation
Snap frozen, fresh tissue was homogenized using Lysing
Matrix A (MP Biomedicals) and a mini bead-beater
(Biospec Products) and RNA was isolated using the
RNeasy kit (Qiagen). Fixed tissue was paraffin-embedded
and RNA was isolated from eight-10 μm FFPE sections.
RNA was isolated using the RecoverAll-MagMAX Cus-
tom Kit and protocol (Applied Biosystems), with the fol-
lowing modifications: RNA isolation digestions were
incubated at 50°C for 15 minutes and then 80°C for 15
minutes, Lysis Binding Solution was reconstituted using
22 ml of 100% isopropanol (Mallinckrodt Chemicals),
Wash Solution 1H was reconstituted using 12 ml of
100% isopropanol (Mallinckrodt Chemicals), and Wash
Solution 2 was reconstituted using 44 ml of 100% etha-
nol (Pharmco-Aaper).
DNA microarray analysis
RNA was amplified according to the Affymetrix One-
Cycle (Affymetrix, Santa Clara, CA) or the MessageAmp
Premier protocol (Ambion). Affymetrix DNA microarray
analysis was prepared according to the manufacturer’s
instructions, and targets were hybridized to the Human
U133A 2.0 GeneChip (Affymetrix, Santa Clara, CA). All
microarray data are available at http://data.genome.duke.
edu/Freedman_CEL_Files and on GEO (GSE29598).
Pre-processing of microarray data
CEL files were RMA normalized using the normalize.R
script (available at http://data.genome.duke.edu/Free-
dman_CEL_Files) run in R (ver2.6.0). CEL files were
MAS5.0 normalized using Expression Console Version
1.1 (Affymetrix). All subsequent statistical analyses were
performed in R/Bioconductor, Partek, MATLAB, and
Eisen’s cluster softwares.
Unsupervised clustering
Hierarchical clustering was performed using Cluster 3.0.
The MAS5.0 normalized data was imported into Cluster
3.0. Data was filtered using the SD (Gene Vector)
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The filtered data was then mean centered for genes and
arrays. Clustering of the adjusted data, genes and arrays,
was done using the correlation (uncentered) similarity
metric and average linkage clustering. The heatmap and
dendogram were visualized using Java TreeView 1.0.12.
Principal components analysis was performed on whole-
genome expression data.
Pathway analysis
The experimental design and statistical models used to
generate patterns of pathway activity in the xenografts
and melanomas were done as previously described
[10,11]. Gene expression signatures to measure the
activity of the RAS and MYC signaling pathways were
built using a Bayesian probit regression model for ‘meta-
gene’ factors from a singular value decomposition of the
top differentially expressed genes. A Monte Carlo Mar-
kov Chain (MCMC algorithm) was used to generate the
predicted probabilities of pathway activity in normalized
investigational samples. See Additional file 1 for greater
detail of pathway analyses.
Results and discussion
The development of genomic signatures reflecting the
activation of cell signaling pathway activity has been
shown to have value in dissecting tumor heterogeneity
[10,11] as well as providing a means to direct the use of
pathway-specific therapies [10,12]. Nevertheless, it has
proven to be difficult to generate robust measures with
genome-wide assays such as DNA microarrays using the
degraded RNA from FFPE samples. Recent work has
described a methodology (MessageAmp Premier) that
has potential to generate useful data from these samples.
Here we focus on an analysis of the capacity of this
methodology to generate consistent biological informa-
tion from FFPE samples that is concordant with results
generated using traditional fresh-frozen samples and a
standard Affymetrix assay. Our strategy makes use of a
collection of precisely matched fresh-frozen and FFPE
tumor tissue samples for validation.
Generation of paired fresh-frozen and FFPE xenograft
samples
In order to generate paired fresh-frozen and FFPE xeno-
graft samples from which gene expression data could be
obtained for comparative purposes, we made use of
human melanoma-derived cell lines grown as xenografts
in a murine model. Human melanoma cells were
injected subcutaneously into the right hind limb of six
week old female nude mice. Five unique human mela-
noma-derived cell lines were injected into five mice
each (~5 × 10
6 cells/injection) generating 25 xenografts.
T h et u m o r sw e r ea l l o w e dt og r o wt o1 0t o1 5m i l l i -
meters in diameter (12 to 33 days) at which point
tumors were harvested and skin removed. Each tumor
was divided with one-half of each tumor snap frozen
while the remaining half was formalin-fixed, paraffin-
embedded.
RNA from the fresh-frozen xenograft samples, as well
as a collection of cells infected with recombinant adeno-
viruses that are used as the source of training data to
develop signatures, was amplified according to the stan-
dard Affymetrix One-Cycle protocol and hybridized to
Affymetrix Human Genome U133A 2.0 arrays. The
quality control metrics for the training samples and
fresh-frozen xenograft samples are consistent with the
general experience of quality measures (Table 1). Aver-
age background values were comparable across all sam-
ples and were within the 20-100 normal range. The
ratios of the signal values of the 3’ probe sets compared
to the corresponding 5’ probe sets for b-actin were at or
below 3 for 24 of 25 samples (ranging from 0.46-3.3).
Similar results were obtained for GAPDH, with all sam-
ples exhibiting ratios below 3 (ranging from 0.94-1.67).
Percent present calls ranged from 49-62% for 24 of 25
samples. Scaling factors were below 3-fold for 23 of 25
s a m p l e s .A ss h o w ni nF i g u r e1 A ,ab o xp l o to ft h el o g
signal intensities shows that samples exhibit consistent
distributions of signal intensities.
The quality control metrics for the RNA from training
samples and fresh-frozen xenograft samples amplified
according to the MessageAmp Premier protocol and
hybridized to Affymetrix Human Genome U133A 2.0
arrays were similar to those obtained for the RNA
amplified according to the Affymetrix One-Cycle proto-
col (summarized in Table 2). As shown in Figure 1B, a
box plot of the log signal intensities shows that all sam-
ples exhibit consistent distributions of signal intensities.
In contrast, the quality control metrics obtained for
the RNA isolated from FFPE xenograft samples, ampli-
fied according to the MessageAmp Premier protocol
and hybridized to Affymetrix Human Genome U133A
2.0 arrays, were indicative of poorer RNA sample quality
Table 1 Quality control metrics for training and fresh-frozen xenograft samples processed using the Affymetrix One-
Cycle protocol
Average Background Value 3’ to 5’ Ratio b-actin 3’ to 5’ Ratio GAPDH Percent Present Scaling Factor
Training Samples 39.9-53.3 1.3-7.21 0.94-1.27 58.1-62.3 1.4-3.62
Fresh-Frozen Xenograft Samples 38.9-54.4 0.46-2.90 0.94-1.67 33.6-59.9 1.4-9.58
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graft samples were within the 20-100 normal range and
were comparable across all samples. Indicative of more
degraded RNA, the ratios of the signal values of the 3’
probe sets compared to the corresponding 5’ probe sets
for b-actin and GAPDH were above 3 for all FFPE
xenograft samples, ranging from 6.32-248. Again
indicative of poorer sample quality, percent present calls
for the FFPE xenograft samples ranged from 8.67-49.7%,
with an average percent present call of 37%. Scaling fac-
tors for FFPE xenograft samples were all above 3-fold
also indicating the existence of more degraded RNA. As
shown in Figure 1C, a box plot of the log signal intensi-
ties shows that the FFPE xenograft samples exhibit a
A.
B.
C.
Figure 1 Distribution of signal intensities. (A) Training samples and fresh-frozen xenografts processed according to the Affymetrix One-Cycle
protocol (B) training samples and fresh-frozen xenografts processed according to the MessageAmp Premier protocol (C) FFPE xenografts
processed according to the MessageAmp Premier protocol. For each sample, the 5
th,2 5
th,5 0
th,7 5
th, and 95
th percentile of the MAS5.0
normalized signal values for all probes on the microarray was calculated. The resulting number was divided by the scaling factor. The logarithm
to the base 2 of the resulting quotient was determined. These numbers are visualized by the box-and-whisker plots.
Table 2 Quality control metrics for training and fresh-frozen xenograft samples processed using the Ambion Message
Amp Premier protocol
Average Background Value 3’ to 5’ Ratio b-actin 3’ to 5’ Ratio GAPDH Percent Present Scaling Factor
Training Samples 33.4-43.3 1.21-8.24 0.92-2.36 58-62.8 1.77-5.74
Fresh-Frozen Xenograft Samples 33-41.5 0.68-5.17 1.01-1.76 36.5-61.6 1.63-14.3
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biting lower signal intensities and more variation in sig-
nal intensities compared to both cell line training and
fresh-frozen xenograft samples.
To evaluate the concordance of whole-genome expres-
sion profiles between arrays processed according to the
Affymetrix One-Cycle protocol and according to the
MessageAmp Premier protocol, unsupervised principal
component analysis and hierarchical clustering were
used to visualize the level of similarity among pairs
from 25 fresh-frozen xenograft samples. As shown in
Figure 2A, principal component analysis (PCA) plot
Table 3 Quality control metrics for FFPE xenograft samples processed using the Ambion Message Amp Premier
protocol
Average Background Value 3’ to 5’ Ratio b-actin 3’ to 5’ Ratio GAPDH Percent Present Scaling Factor
FFPE Xenograft Samples 28.7-36 6.32-248 19.1-176 8.67-49.7 7.52-121
͘ ͘ ͘
͘ ͘ &͘
Figure 2 Patterns of whole-genome expression among paired samples. (A) Principal component analysis of the MAS5.0 normalized gene
expression data from the fresh-frozen xenografts processed with the Affymetrix One-Cycle versus MessageAmp Premier protocol. Shapes
represent samples; Affymetrix One-Cycle in black and MessageAmp Premier in red. (B) Unsupervised hierarchical clustering of the MAS5.0
normalized gene expression data from fresh-frozen xenografts processed with the Affymetrix One-Cycle versus MessageAmp Premier protocol.
Columns represent samples; rows represent genes; higher expression in red and lower in green. Color bar below data matrix defines Affymetrix
One-Cycle in blue and MessageAmp Premier in red. Second color bar defines samples associated with DM6 in dark blue, DM366 in light blue,
DM440 in green, DM443 in orange, and DM738 in red. (C) Pearson correlation coefficients for whole-genome expression data from matched and
unmatched pairs of fresh-frozen xenografts processed according to the Affymetrix One-Cycle versus MessageAmp Premier protocol. (D) Principal
component analysis of the MAS5.0 normalized gene expression data from fresh-frozen xenografts versus FFPE xenografts processed with the
MessageAmp Premier protocol. Shapes represent samples; fresh-frozen in black and FFPE in red. (E) Unsupervised hierarchical clustering of the
MAS5.0 normalized gene expression data from fresh-frozen xenografts versus FFPE xenografts processed with the MessageAmp Premier protocol.
Representations are as in (B), except the color bar below the data matrix defines fresh-frozen samples in blue and FFPE samples in red. (F)
Pearson correlation coefficients for whole-genome expression data from matched and unmatched pairs of fresh-frozen xenografts versus FFPE
xenografts processed with the MessageAmp Premier protocol.
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data for a given fresh-frozen xenograft sample processed
according to the Affymetrix One-Cycle protocol as com-
pared to the MessageAmp Premier protocol (for princi-
pal component analyses in greater than two dimensions
and a graph depicting the percentage of variance that
each principal component captures see Additional file
2). In addition, a heatmap with hierarchical clustering of
fresh-frozen xenograft samples demonstrates the gene
expression patterns observed within xenograft sample
pairs processed according to the two methods (Figure
2B). Furthermore, the average Pearson correlation coef-
ficient (0.973, range [0.965, 0.981]) for whole-genome
expression data obtained from samples processed
according to the Affymetrix One-Cycle protocol versus
the MessageAmp Premier protocol show much greater
agreement than among unmatched pairs (0.886, range
[0.673, 0.978]) (Figure 2C) (for a heat map representing
the correlation coefficients see Additional file 3).
The same analyses were performed to assess the level
of correlation between whole-genome expression data
obtained from paired fresh-frozen and FFPE xenograft
samples processed according to the MessageAmp Pre-
mier protocol. As shown in Figure 2D, PCA plot indi-
cates the whole-genome expression data for a given
fresh-frozen xenograft sample is different than the
whole-genome expression data for the paired FFPE
xenograft sample (for principal component analyses in
greater than two dimensions and a graph depicting the
percentage of variance that each principal component
captures see Additional file 4). In addition, a heatmap
with hierarchical clustering of fresh-frozen and FFPE
xenograft samples shows that clustering is driven by
whether a xenograft sample is of fresh-frozen or FFPE
origin rather than by differences in gene expression data
between different individual xenografts (Figure 2E).
Furthermore, Pearson correlation coefficients measured
within a given pair of fresh-frozen versus FFPE xeno-
graft samples are no higher than across unmatched sam-
ples (Figure 2F) (for a heat map representing the
correlation coefficients see Additional file 5).
Predictive capacity of pathway signatures in fresh-frozen
and formalin fixed, paraffin-embedded xenograft samples
Although whole-genome expression data correlates
poorly between paired fresh-frozen and FFPE xenograft
samples, the critical question is the extent to which use-
ful and consistent information about the underlying
biology can be obtained from the FFPE samples. We
have previously made use of gene expression signatures
developed to measure the activity of a number of onco-
genic signaling pathways to explore the underlying biol-
ogy of tumor samples [10,11,13]. At the same time,
these pathway signatures have been shown to predict
sensitivity to various cancer drugs that target compo-
nents of the relevant pathway and thus provide the
further benefit of potentially identifying therapeutic
options for subgroups of patients [10,12]. We predicted
the activity of the RAS and MYC pathways in the paired
fresh-frozen and FFPE xenograft samples, leading to the
generation of probability measures that have been
shown in previous work to reflect the state of pathway
activity as measured by various biochemical assays.
To obtain total RNA for training data, human mam-
mary epithelial cells (HMECs) were infected with a
recombinant adenovirus containing either a control
insert expressing GFP (eight replicates), an insert
expressing RAS (eight replicates), or an insert expressing
MYC (six replicates). Total RNA isolated from these
cells was amplified using the MessageAmp Premier pro-
tocol. For comparison, total RNA isolated from these
cells was also amplified using the Affymetrix One-Cycle
protocol. Similarly, for the fresh-frozen xenograft sam-
ples, total RNA isolated from the tumors was amplified
using the MessageAmp Premier protocol and, for com-
parison, the total RNA isolated from the tumors was
also amplified using the Affymetrix One-Cycle protocol.
For the FFPE xenograft samples, total RNA isolated
from the tumors was amplified using the MessageAmp
Premier protocol. All amplified RNA was hybridized to
Affymetrix Human Genome U133A 2.0 arrays.
For comparison, to build the predictive models from
whole-genome expression data we fit a Bayesian regres-
sion model to metagene factors of differentially
expressed genes of RAS and MYC pathway activity in
HMECs. The models are then used to predict the activa-
tion status in fresh-frozen xenograft samples processed
according to the Affymetrix One-Cycle protocol versus
the MessageAmp Premier protocol. As shown in Figure
3A, predictors from either protocol consisting of 350
genes or 500 genes were selected to differentiate
between HMECs expressing RAS and MYC, respectively,
relative to HMECs expressing GFP. Probes are provided
in Additional file 6 for each signature. The Bayesian
models were then used to predict the probability of RAS
and MYC pathway activity in the fresh-frozen xenograft
samples processed according to the Affymetrix One-
Cycle protocol versus the MessageAmp Premier proto-
col. As shown in Figure 3B, the probability of RAS and
MYC pathway activities correlates extremely well
b e t w e e nag i v e np a i ro ff r e s h - f r o z e nx e n o g r a f ts a m p l e s
processed according to the Affymetrix One-Cycle proto-
col versus the MessageAmp Premier protocol (RAS p <
0.0001, MYC p = 0.011).
A ss h o w ni nF i g u r e4 ,w ep r e d i c t e dt h ea c t i v i t i e so f
the RAS and MYC pathways in the fresh-frozen and
FFPE xenograft samples to determine if consistent infor-
mation about the status of oncogenic signaling pathway
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paired fresh-frozen and FFPE xenograft samples. As
shown in Figure 4A, a predictor consisting of 200 genes
or 500 genes differentiates between HMECs expressing
RAS and MYC, respectively, relative to HMECs expres-
sing GFP. These predictors were then used to predict
the status of the RAS and MYC pathways in the fresh-
frozen and FFPE xenograft samples processed according
to the MessageAmp Premier protocol. As shown in Fig-
ure 4B, the predicted probability of RAS and MYC path-
way activity correlates extremely well between a given
pair of fresh-frozen and FFPE xenograft samples (RAS p
= 0.0003, MYC p = 0.0013).
Prediction of signaling pathways in patient matched
fresh-frozen and formalin-fixed, paraffin-embedded
melanoma samples
Having demonstrated that the status of oncogenic sig-
naling pathways can be consistently predicted using
gene expression data obtained from paired fresh-frozen
and FFPE xenograft samples, we investigated whether
the status of oncogenic signaling pathways could also be
consistently predicted using gene expression data
obtained from patient matched fresh-frozen and FFPE
melanomas. Fresh-frozen samples for these analyses
consisted of in-transit melanomas from 6 patients
obtained before the initiation of melphalan isolated limb
infusion chemotherapy. Previous work has predicted the
status of oncogenic signaling pathways in these samples
and has shown that the status of a particular oncogenic
signaling pathway is concordant across the lesions from
a given patient, with the range of predictions not
exceeding 0.3 in 70% or more of the patients [14]. FFPE
tissue from a lesion from each patient within a month
prior to the initiation of melphalan isolated limb infu-
sion chemotherapy was obtained and the status of the
RAS and MYC oncogenic signaling pathways were pre-
dicted. As shown in Figure 5, RAS pathway status
showed a strong concordance (100%) in fresh-frozen
and FFPE samples from a given patient, as the difference
in the probability of RAS pathway activity in the FFPE
samples and at least one of the fresh-frozen in-transit
lesions did not exceed 0.3 for any of the patients. The
average within-sample differences seen in patients was
0.184 (ranging from 0.007 to 0.314). MYC pathway sta-
tus also showed a strong concordance (83%) in fresh-
frozen and FFPE samples from a given patient, as the
difference in the probability of MYC pathway activity in
the FFPE samples and at least one of the fresh-frozen
in-transit lesions did not exceed 0.3 for 5 of the 6
Control RAS Control RAS
MAP OneͲCycle
MAP OneͲCycle
Control MYC Control MYC
A. B.
p<0.0001
p=0.011
Figure 3 Status of RAS and MYC pathway activities in fresh-frozen xenografts processed according to the Affymetrix One-Cycle
protocol compared to the MessageAmp Premier protocol. (A) Heatmaps representing the expression levels of genes comprising the gene
expression signature that differentiates between HMECs infected with adenovirus expressing GFP (control) versus HMECs infected with
adenovirus expressing RAS or MYC as indicated. Within the heatmap, columns represent samples and rows represent genes, with expression
values on a low to high continuum represented by a blue to red continuum, respectively. (B) Scatterplot of the Affymetrix One-Cycle protocol
(X-axis) versus the MessageAmp Premier protocol (Y-axis) for the RAS pathway (top) or MYC pathway (bottom). The simple linear regression
model and p-value is drawn for each Pearson correlation.
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patients was 0.182 (ranging from 0.019 to 0.367).
Conclusions
Genomic profiling has been shown to play an important
role in characterizing distinct forms of cancers on the
basis of patterns of gene expression and functions asso-
ciated with genes relevant to profiles. These characteri-
zations provide potential approaches to further
understand the biology underlying individual tumors
and to develop new targeted therapeutic options for
subgroups of patients, matching targeted therapies in a
rational way with characteristics of the patient’st u m o r .
An ability to use FFPE tissue samples for gene expres-
sion profiling will facilitate the number and type of
available samples for research analyses as well as allow
these assays to be done in a clinical setting.
Prior studies have described the use of Quantitative
Real-Time Polymerase Chain Reaction (QRT-PCR)
assays as a method to measure gene expression within
FFPE tumor tissue samples. While these assays can be
informative with respect to measuring the expression of
specific genes in a tumor sample, this approach does
not provide a basis for whole genome expression mea-
surement. As such, only a restricted view of the underly-
ing biology of the tumor can be obtained and discovery
of new genomic profiles relevant to the tumor cannot
be generated. Thus, the capacity to employ whole-gen-
ome expression measurements from FFPE tumor tissue
samples is critical.
The work we describe here demonstrates the develop-
ment of an assay to enable genomic signatures that can
measure deregulation of various oncogenic signaling
pathways to be applied to FFPE tumor tissue samples.
Although genome wide expression data correlates poorly
between paired fresh-frozen and FFPE xenograft sam-
ples, it is apparent that consistent and reliable genomic
profiles reflecting activities of oncogenic signaling path-
ways comprised of a subset of probes that exhibit a con-
sistent pattern of expression associated with the
expression of the activated oncogene can be generated.
We believe this reflects the complexity of these cell sig-
naling pathways combined with the power of the signa-
ture development approach whereby the capacity to
sample a diverse array of expression values can yield
measures of pathway activity. We have shown that RNA
isolated from FFPE tumor tissue samples, amplified fol-
lowing the MessageAmp Premier protocol, and hybri-
dized to Affymetrix arrays can be used to generate
consistent and reliable genomic profiles reflecting RAS
and MYC pathway activity. We have shown significant
correlations between predictions of the status of the
Control RAS A.
MAP
Control MYC
MAP
B.
P=0.0003
p=0.0013
Figure 4 Status of RAS and MYC pathway activities in paired fresh-frozen and FFPE xenografts. (A) Heatmaps representing the expression
levels of genes comprising the gene expression signature that differentiates between HMECs infected with adenovirus expressing GFP (control)
versus HMECs infected with adenovirus expressing RAS or MYC as indicated. Within the heatmap, columns represent samples and rows
represent genes, with expression values on a low to high continuum represented by a blue to red continuum, respectively. (B) Scatterplot of the
fresh-frozen xenografts (X-axis) versus the FFPE xenografts (Y-axis) for the RAS pathway (top) or MYC pathway (bottom). The simple linear
regression model and p-value is drawn for each Pearson correlation.
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FFPE xenograft samples. In addition, we have shown sig-
nificant correlations between the pathway predictions in
patient matched fresh-frozen and FFPE melanoma sam-
ples. In future work it will be critical to evaluate the
ability of this assay to generate valid genomic predic-
tions from prospectively collected FFPE samples in a
clinical trial.
An ability to generate quality whole-genome expres-
sion data from FFPE tumor tissue samples allows the
large number of currently banked samples to be used in
genomic profiling analyses. This not only gives
researchers access to a tremendous number of samples,
but also allows researchers to utilize samples from
patients for which clinical outcomes are known.
Furthermore, the ability to generate genomic profiles
using this assay from prospectively collected FFPE
tumor tissue samples in clinical trials has the potential
to enable clinicians to utilize the information of the
underlying biology of tumors from individual patients to
more accurately diagnose an individual patient’s disease,
more properly predict the course of an individual
patient’s disease, and more rationally match therapeutic
options with an individual patient’s disease.
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Figure 5 Status of RAS and MYC pathway activities in patient matched fresh-frozen and FFPE melanomas. Graphs represent the pathway
predictions for the status of the RAS pathway (top) and MYC pathway (bottom) in fresh-frozen and FFPE samples for patients as indicated. Blue
bars represent fresh-frozen samples and red bars represent FFPE samples.
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Additional file 1: Supplementary methods. A supplementary methods
file including greater detail of pathway analyses.
Additional file 2: Principal component analyses of the MAS5.0
normalized gene expression data from the fresh-frozen xenografts
processed according to the Affymetrix One-Cycle protocol versus
the MessageAmp Premier protocol. (A) Principal component analyses
in greater than 2 dimensions. Shapes represent samples and colors
represent the processing protocol used, with all samples processed
according to the Affymetrix One-Cycle protocol depicted in black and all
samples processed according to the MessageAmp Premier protocol
depicted in red. (B) Graph depicting the percentage of variance that
each principal component captures.
Additional file 3: Heat map representing the correlation coefficients
for whole-genome expression data obtained from fresh-frozen
xenografts processed according to the Affymetrix One-Cycle
protocol versus the MessageAmp Premier protocol. Within the heat
map, columns represent fresh-frozen xenografts processed according to
the MessageAmp Premier protocol and rows represent fresh-frozen
xenografts processed according to the Affymetrix One-Cycle protocol.
Correlation coefficients represented on a yellow to red continuum, as
indicated.
Additional file 4: Principal component analyses of the MAS5.0
normalized gene expression data from the fresh-frozen xenografts
versus the FFPE xenografts processed according to the
MessageAmp Premier protocol. (A) Principal component analyses in
greater than 2 dimensions. Given pairs of fresh-frozen and FFPE samples
are depicted by the same shape with fresh-frozen samples depicted in
black and FFPE samples depicted in red. (B) Graph depicting the variance
that each principal component captures.
Additional file 5: Heat map representing the correlation coefficients
for whole-genome expression data obtained from fresh-frozen
xenografts versus FFPE xenografts processed according to the
MessageAmp Premier protocol. Within the heat map, columns
represent fresh-frozen xenografts and rows represent FFPE xenografts.
Correlation coefficients represented on a yellow to red continuum, as
indicated.
Additional file 6: Probes comprising signatures. A file including the
probes comprising each signature.
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